Chesapeake Urology

Nov 6, 2023 | onclive.com | Benjamin H. Lowentritt |Chesapeake Urology

November 6, 2023Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer. Benjamin H. Lowentritt, MD, FACS, director, Minimally Invasive Surgery and Robotics, Chesapeake Urology, discusses the exploration of active surveillance in patients with prostate cancer.

Jul 18, 2023 | onclive.com | Benjamin H. Lowentritt |Chesapeake Urology

Benjamin H. Lowentritt, MD, FACS, director, Minimally Invasive Surgery and Robotics, Chesapeake Urology, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen (PSA) responses generated from second-generation androgen receptor (AR) inhibitors in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Jul 13, 2023 | onclive.com | Benjamin H. Lowentritt |Chesapeake Urology

Benjamin H. Lowentritt, MD, FACS, director, Minimally Invasive Surgery and Robotics, Chesapeake Urology, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors (ARSIs) in patients with metastatic castration-sensitive prostate cancer (mCSPC) could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.

May 24, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications

May 17, 2023 | onclive.com | Alan Bryce |Elisabeth I. Heath |Benjamin H. Lowentritt |Chesapeake Urology |Edwin M. Posadas |Tian Zhang

OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications